Pison is advancing the frontier of human potential with the world’s first AI-infused, neural biosensing platform. Patented, non-invasive electroneurography (ENG) algorithms create life-changing applications in cognitive performance, disease diagnostics and management, and ongoing care. Pison began in 2016 with funding from the Massachusetts Institute of Technology, National Science Foundation and the ALS Association to help patients with neurodegenerative disorders better navigate the world made smaller by their diseases. Investors and partners include First Round DRF, Oculus, MIT, Draper, HHS, National Science Foundation, Bose Ventures, and In-Q-Tel. By harnessing the power of the mind in real-time, users gain access to better health and higher achievement in every domain while reaching peak mental and physical performance on the playing field, in the office, and behind the wheel of a car.